Aera Therapeutics is a biotechnology company leveraging its proprietary protein nanoparticle (PNP) delivery platform to unlock the full potential of genetic medicines
Aera Therapeutics is a biotechnology company leveraging its proprietary protein nanoparticle (PNP) delivery platform to unlock the full potential of genetic medicines. Aera’s platform, based on endogenous human proteins, is being developed to address the limitations of today’s delivery technologies and to expand the reach of genetic medicines to different tissues and applications, in order to benefit more patients across more disease areas.